Ra Capital Management, L.P. Aerovate Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $4.82 Billion
- Q1 2025
A detailed history of Ra Capital Management, L.P. transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 9,192,092 shares of AVTE stock, worth $24.6 Million. This represents 0.48% of its overall portfolio holdings.
Number of Shares
9,192,092
Previous 9,192,092
-0.0%
Holding current value
$24.6 Million
Previous $24.4 Million
5.28%
% of portfolio
0.48%
Previous 0.39%
Shares
3 transactions
Others Institutions Holding AVTE
# of Institutions
85Shares Held
32.3MCall Options Held
30.3KPut Options Held
57.9K-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$10.1 Million0.69% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$6.01 Million1.35% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$4.82 Million1.32% of portfolio
-
Adar1 Capital Management, LLC Austin, TX1.46MShares$3.92 Million0.68% of portfolio
-
Braidwell LP Stamford, CT1.44MShares$3.86 Million0.22% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $65.5M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...